Figure 3
From: ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer

ALKBH4 knockdown induced G1 phase arrest in NSCLC cells. A549 cells (A) or II-18 cells (B) were transfected with ALKBH4 siRNAs or control siRNA for 48 h and the cell cycle was analysed using a flow cytometer. Values are represented as means ± S.D. of three independent experiments. *p < 0.05; **p < 0.01 vs. control siRNA (One-way ANOVA with Bonferroni post-hoc tests). (C) Lysates of A549 cells transfected with ALKBH4 siRNAs or control siRNA were subjected to Western blot analysis with anti-CDK2, anti-CDK4, anti-Cyclin D3, and anti-β-actin antibodies. Uncropped Western blot data are shown in Supplementary Fig. S9. Representative pictures of three independent experiments are shown. (D) NCI-H23 cells were transfected with wild-type ALKBH4 or mutant ALKBH4 for 48 h and the cell cycle was analysed using a flow cytometer. Values are represented as means ± S.D. of three independent experiments. ***p < 0.001; ****p < 0.0001 (One-way ANOVA with Bonferroni post-hoc tests). (E) A549 cells were transfected with ALKBH4 siRNAs or control siRNA for 48 h and the apoptosis was analysed using a flow cytometer. Values are represented as means ± S.D. of three independent experiments. **p < 0.01 vs. control siRNA (One-way ANOVA with Bonferroni post-hoc tests).